HomeNewsBusinessPersonal FinanceCOVID-19 claims: General Insurance Council’s tariff card explained

COVID-19 claims: General Insurance Council’s tariff card explained

The indicative COVID-19 hospital tariff proposed by the General Insurance Council may reduce disputes between hospitals and insurers

July 08, 2020 / 10:58 IST
Story continues below Advertisement

The General Insurance Council (GI Council), the non-life insurance industry association, has come out with an indicative rate chart for COVID-19 hospitalisation claims. The tariff has been devised after discussion with the medical professionals employed with insurance companies, the council said. The rates will be applicable to both cashless and reimbursement claims. However, in case a government authority has prescribed treatment charges in a state or city, those charges will apply. The Council-devised charge structure will be reviewed every month. Here is what the development means for policyholders (who may be patients).

What is the rationale behind devising this rate chart?

Story continues below Advertisement

Since the beginning of the COVID outbreak, insurers and hospitals have often been locked in disputes over expenses payable. The objective is to bring about some clarity on what is payable, and the expenses that will not be reimbursed. “COVID-19 is a new illness with no established protocols and standardised treatment costs. This may, at times, result in an insurance company raising questions on the amounts spent,” the industry body’s statement noted. Due to such disputes, patients suffer a loss. As per the GI Council, the rate chart is an attempt at allaying policyholders’ fears and bringing clarity to the treatment of COVID-19 claims.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show